Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Evotec SE Investor Presentation 2012

Jul 10, 2012

151_ip_2012-07-10_8438e2c3-df36-43fa-9d32-39ffc6eb5521.pdf

Investor Presentation

Open in viewer

Opens in your device viewer

{# SEO P0-1: filing HTML is rendered server-side so Googlebot sees the full text without executing JS or following an iframe to a Disallow'd CDN path. The content has already been sanitized through filings.seo.sanitize_filing_html. #}

Add g ressing causes not in diabetes sy po m t ms

Evotec AG , Analyst information on CureBeta Alliance with Janssen, H Hamburg, 2012

Forward-looking s statements

Information set forth in this presen forward-looking statements, which invo risks and uncertainties ncertainties. The forward forward-lo contained herein represent the judgemen the date of this report. Such forward-lo are neither promises nor guarantees, bu variety of risks and uncertainties, man ntation containsolve a number ofoking statements nt of Evotec as ofooking statements ut are subject to a ny of which are

beyond our control, and which could cause actual results to differ materially from those contemplated in these forward looking statements We e pressl disclaim an forward-lookingstatements. expressly any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

Agenda

• CureBeta & Strategic c background

  • • Scientific vision and disccovery background & other Cure X initiatives
  • •Next steps

Cure X - First-in-cl a key building bloc lass science ck of Action Plan 2016

Evotec´s offering for Inno ovation Efficiency

• No risk-exposure, lower margin, but long-term repeat t business

Summary – "Win – Win –

"W
"
S
W
W
S
i
i
i
i
i
t
t
m
m
a
r
n
n
n
a
o
n
u
y
u
–
–
–
C
B
t
r
e
e
a
u
t
e
r
m
s		 \$
\$
S
S
U
f
U
M
i
i
l
i
l
b
U
M
i
d
8
2
0
0
3
0
0
t
t
t
t
t
t
p
r
o
n
o
p
o
e
n
a
m
e
s
o
n
e
s
a
o
o
p
e
r
p
r
o
c
u
u
•
-
,
(
l
i
i
l,
l
i
i
l,
l
i
l
),
t
p
r
e
-c
n
c
a
c
n
c
a
r
e
g
a
o
r
c
o
m
m
e
r
c
a
u
y,
R
l
i
t
o
y
a
e
s
•
R
h
t
e
s
e
a
r
c
p
a
y
m
e
n
s
•
/
/
W
i
W
i
W
i
n
n
n
l
l
i
a
a
n
c
e		 J
A
l
i
f
l
i
f
l
l
l
l
d
b
i
l
i
h
t
t
a
n
s
s
e
n
:
c
c
e
s
s
o
a
n
e
x
c
u
s
v
e
p
o
r
o
o
o
s
m
a
m
o
e
c
u
e
a
n
o
o
g
c
r
e
s
e
a
r
c
p
r
o
g
r
a
m
s
•
f
d
h
i
f
i
l
i
d
i
b
l
l
i
l
i
h
d
i
b
t
t
t
t
t
o
c
s
e
o
n
e
r
e
g
e
n
e
r
a
o
n
o
n
s
s
n-
p
r
o
c
n
g
e
a
c
e
s
n
p
e
o
p
e
a
e
e
s
u
u
u
w
E
E
d
i
l
d
h
i
i
b
l
l
i
h
i
h
l
i
b
i
d
d
t
t
t
t
t
v
o
e
c
x
p
a
n
n
g
e
a
e
r
s
p
n
e
a
c
e
r
e
g
e
n
e
r
a
o
n
g
y
s
y
s
e
m
a
c,
u
n
a
s
e
a
n
:
•
-
h
i
h
b
l
l
l
i
i
t
t
t
c
o
m
p
r
e
e
n
s
e
a
p
p
r
o
a
c
o
e
a
c
e
r
e
p
c
a
o
n
v
H
d
A
l
i
d
l
f
i
i
i
i
h
i
l
i
d
t
t
t
t
a
r
v
a
r
c
c
e
e
r
a
n
g
e
v
e
o
p
m
e
e
n
o
n
n
o
v
a
v
e
s
c
e
n
c
e
w
c
o
m
m
e
r
c
a
u
p
s
e
:
•
S
i
i
t
t
t
a
r
n
g
p
o
n
f
i
i
t
o
r
n
n
o
v
a
o
n
f
f
i
i
d
e
c
e
n
c
y
a
n
l
t
e
x
e
r
n
a
i
i
t
n
n
o
v
a
o
n		 f
P
h
i
d
i
h
h
&
k
h
d
l
t
t
t
t
t
t
t
a
r
m
a
n
u
s
r
y
a
p
p
r
e
c
a
e
s
e
e
a
p
p
r
o
a
c
s
e
e
m
s
e
e
n
o
e
n
e
r
e
s
e
y
p
e
o
e
a
s
•
O
i
l
l
i
l
f
d
i
l
b
i
h
i
d
t
t
t
t
t
t
t
t
t
p
m
a
r
a
n
s
a
o
n
a
s
r
a
e
g
o
o
r
a
c
a
e
m
a
o
r
e
a
r
o
e
c
e
a
s
a
s
a
r
g
e
s
g
e
y
y
•
i
d
i
l
h
d
i
f
t
t
t
m
m
e
a
e
o
n
p
a
r
m
a
g
r
a
e
n
n
r
a
s
r
c
r
e
s
y
u
u
B
i
l
d
i
C
X
l
f
h
d
d
l
i
d
t
n
g
r
e
p
a
o
r
m
s
a
s
a
p
s
e
u
u
u
u
•
B
i
l
d
i
i
f
f
E
V
T
T
I
b
i
i
f
i
l
d
t
t
t
t
n
g
n
r
a
s
r
c
r
e
o
r
n
e
g
r
a
e
s
n
e
s
s
n
n
e
e
s
u
u
u
u
w
−
B
i
l
d
i
l
j
f
l
i
f
E
V
T
I
l
l
i
t
t
t
t
n
g
e
a
r
s
a
g
e
p
r
o
e
c
p
o
o
r
o
o
s
o
r
n
n
o
a
e
a
a
n
c
e
s
u
y
v
−

Great Partners

Who is CureBeta1)?

Bringing best of sc cience and industry together

Quotes from Evotec – Jan nssen - JDRF

"Our collaboration with Doug Melton's laboratory has been extremely suc levels We have not only achieved our scientific goals of creating a super levels. discovery platform and generating a deep pipeline of novel and exciting t also established a new model of collaboration between academia and indhighly efficient and effective in accelerating innovative scientific developm Pharmaceuticals perfectly complements this effort, bringing in world-lead d l t ti ll th t t development expertise as well as the necessary resources to execute on produce first-in-class therapeutics designed to restore beta cell mass and ccessful on multiple rior beta cell drug targets, but we have dustry that has proven ment. Janssen ding pharmaceutical n our mii t ss on to d function."

Dr. Cord DohrmannChief Scientific Officer of Evotec

"Beta cell survival and function play a critical role in maintaining normal l l l d h th i d l glucose levels and when they are compromised, can contribute to the onset of diabetes. This collaboration strengthens our long term diabetes development pipeline and directly reflects our commitment to making a difference for the millions of people worldwide living with this disease."

Peter DiBattiste, M.D., Global Therapeutic Head, Cardiovascular and Metabolism at Janssen

"We are delighted to see Evotec, Dr. Doug Melton, and Janssen launch this collaborative partnership and commitment to develop innovative regenerative medicine therapies for diabetes. JDRF looks forward to supporting the supporting CureBeta initiative initiative."

Dr. Richard Insel, Chief Scientific Officer Juvenile Diabetes Research Foundation (JDRF)

Agenda

  • • CureBeta & Strategic background
  • • Scientific vision and dinitiativesiscovery background & other Cure X
  • •Next steps

Why is there such a dramatic unmet medical need?

Important Facts about Dia abetes

Multip gy le highly inn modifying approac novative, p y otentially disease ches

Evotec's unique diabetes f franchise

Stat tus discovery

Combining p to sci platforms for big u ience with unmet medical need

What defines first-in-classs innovation infrastructure?

F
o
c
s
u		 I
t
t
n
e
g
r
a
e		 i
E
n
g
n
e
e
r		 S
c
r
e
e
n
d
i
d
i
f
i
s
e
a
s
e
m
o
y
n
g
h
i
m
e
c
a
n
s
m
s		 i
i
i
h
i
t
e
m
e
r
g
n
g
n
s
g
s
n
d
i
b
i
l
s
e
a
s
e
o
o
g
y		 d
l
i
h
h
i
h
t
m
o
e
s
w
g
e
r
d
i
b
i
l
i
t
t
p
r
e
c
a
y		 i
l
l
t
t
s
y
s
e
m
a
c
a
y
,
b
i
d
&
u
n
a
s
e
h
i
c
o
m
p
r
e
e
n
s
v
e
C
f
l
b
i
i
t
t
t
t
e
a
r
e
n
e
o
p
a
e
n
s
•
O
b
i
d
i
f
f
i
i
t
t
v
o
u
s
e
r
e
n
a
o
n
•
i
i
h
i
t
t
t
o
e
s
n
g
e
r
a
p
e
s
x
T
b
l
i
d
t
r
a
c
a
e
n
r
g
u
•
d
i
s
c
o
v
e
r
y
p
r
o
c
e
s
s		 A
l
i
i
h
k
i
i
t
g
n
w
e
y
o
p
n
o
n
•
l
d
i
d
i
e
a
e
r
s
n
a
c
a
e
m
a
E
b
l
i
h
t
s
a
s
n
e
w
•
l
l
b
i
d
l
t
c
o
a
o
r
a
o
n
m
o
e
s
A
i
i
i
t
c
q
u
r
e
n
n
o
v
a
v
e
•
l
d
t
t
o
o
s
a
n
a
s
s
e
s		 R
l
h
t
e
e
v
a
n
c
e
o
u
m
a
n
•
d
i
s
e
a
s
e
P
i
i
d
i
t
t
r
o
m
o
s
e
a
s
e
x
y
•
i
f
i
h
i
s
p
e
c
c
m
e
c
a
n
s
m
C
C
b
i
H
d
t
o
m
n
e
r
e
a
o
u
s
•
i
h
h
h
t
t
t
w
r
o
u
g
g
p
p
u		 L
d
i
e
v
e
r
a
g
e
s
e
a
s
e
•
f
d
l
t
t
m
o
e
s
o
r
a
r
g
e
s
d
d
a
n
c
o
m
p
o
u
n
s
A
i
d
b
i
d
o
a
s
e
v
•
h
a
p
p
r
o
a
c
e
s
C
h
i
d
t
o
m
p
r
e
e
n
s
v
e
a
a
•
i
d
i
i
t
s
e
s
m
p
r
o
v
e
e
c
s
o
n
k
i
m
a
n
g

Systematic, unbias mechanism-focusesed and comprehensive ed infrastructures

The CureBeta " "Autobahhn"

High
Resolution
Expression
Profiling		 • Transcriptome / proteome analysis
• Profiling of specific cells and tissues
- Disease relevant mechanisms
- Longitudinal analysis of disease progression		 Pipeline of
selected
Mechanism
Focused
Chemical
Genomics		 • Mechanisms focused cellular assay
- Primary cells / tissues
- Immortalized cells
• High content screening of
- Annotated libraries
- Diverse libraries
- Natural products		 First in class
Candidate
Leads /
Targets		 Targets and
Leads
advance into
Drug
Discovery
Process
High
Content
Functional
Genetics		 • Sophisticated high content cellular assay
• Loss of function
• Gain of function
• High content readouts

CureBeta - – Estaablishing infrastructure standards

Targets, assays, models, an nalysis…

3

  • •Secreted factors
  • •Small molecule

Pancreas of a male ZDF ratRed: BrdU; green: Insulin; blue: DAPI 21 megapixel image composite taken at 10x magnification

Islets Degeneration in Type 2 diabetes

Key mechanisms r regulating beta cell mass

Beta cell replication and in nsulin resistance

Building a Cure X pipeline

High unmet medical need and paucity of disease modifying targets…

C
B
t
u
r
e
e
a		 S
d
l
l
b
i
i
h
H
d
U
i
i
i
M
h
2
0
1
1
t
t
t
t
t
a
r
e
c
o
a
o
r
a
o
n
w
a
r
v
a
r
n
v
e
r
s
y
n
a
r
c
•
P
d
i
h
J
i
J
l
2
0
1
2
t
t
a
r
n
e
r
e
a
n
s
s
e
n
n
w
u
y
•
C
N
h
u
r
e
e
p
r
o
n		 S
d
l
l
b
i
i
h
H
d
U
i
i
i
F
b
2
0
1
2
t
t
t
t
t
a
r
e
c
o
a
o
r
a
o
n
w
a
r
v
a
r
n
v
e
r
s
y
n
e
r
u
a
r
y
•
H
i
h
l
d
i
i
i
d
i
d
&
d
t
t
t
t
t
g
p
r
o
c
e
n
g
e
n
e
e
r
a
n
g
c
a
n
a
e
a
r
g
e
s
c
o
m
p
o
n
s
y
u
v
u
•
M
k
i
f
f
i
l
l
i
S
b
2
0
1
2
t
t
t
t
t
a
r
e
n
g
e
o
r
s
w
s
a
r
n
e
p
e
m
e
r
•
C
N
u
r
e
e
u
r
o
n		 C
h
f
i
l
j
t
t
t
o
n
c
e
p
p
a
s
e
o
r
n
e
r
n
n
a
p
r
o
e
c
s
•
E
l
i
i
l
l
l
b
b
i
i
i
t
t
t
t
t
p
o
r
n
g
p
o
e
n
a
c
o
a
o
r
a
o
n
o
p
p
o
r
n
e
s
x
u
•
C
H
t
u
r
e
e
a
r		 C
f
h
i
l
j
t
t
t
o
n
c
e
p
p
a
s
e
o
r
n
e
r
n
n
a
p
r
o
e
c
s
•
E
l
i
i
l
l
l
b
b
i
i
i
t
t
t
t
t
p
o
r
n
g
p
o
e
n
a
c
o
a
o
r
a
o
n
o
p
p
o
r
n
e
s
x
u
•

Agenda

  • • CureBeta & Strategic c background
  • • Scientific vision and disccovery background & other Cure X initiatives
  • •Next steps

CUREBETA - disruuptive innovation in diabetes

BETALunch in Harvard: TThe root cause – Not the symptoms

BETALunch, Scientific Workshop, Fall 2012 1)

Workshop / Scientific Seminar on

  • •Disease modifying drugs in diabetes
  • • B t ll d f ti i t l f th Beta cell mass and function are pivotal for the development of disease modifying drugs
  • • Systematic, unbiased and comprehensive appr b t ll ti beta cell regeneration roach to
  • • Unique tools and models for the target/drug dis and rapid development covery
  • • Combining leading expertise in academic beta c biology, biotech discovery and pharma develop cell pment

Key Contributions

Doug Melton, others

Prof Doug Melton

Strong news flow to come

Outlook and next steps for r 2012 ff

Key milestones for 2012

E
V
T
E
t
1
x
e
c
u
e		 D
b
l
d
i
i
h
2
0
1
2
2
0
1
6
t
t
o
e
g
r
e
e
n
e
g
r
o
o
u
v
u
w
•
–
f
E
i
i
i
l
l
i
t
x
p
a
n
s
o
n
s
u
c
c
e
s
s
o
e
x
x
s
n
g
a
a
n
c
e
s
•
S
f
i
i
i
l
d
l
i
h
j
h
t
t
t
g
n
c
a
n
o
n
g
e
r
m
e
a
a
s
w
m
a
o
r
p
a
r
m
a
•
-
E
V
T
I
t
t
2
n
e
g
r
a
e		 f
f
/
/
A
l
2
2
i
i
i
i
i
i
i
i
d
d
h
h
l
l
d
d
i
i
l
l
i
t
t
t
t
t
t
t
t
t
t
e
a
s
s
g
n
c
a
n
n
e
w
w
n
e
g
r
a
e
e
c
n
o
o
g
y
s
e
a
s
e
a
a
n
c
e
s
•
f
/
D
l
i
i
i
i
d
l
d
l
i
i
l
l
i
i
l
i
l
t
t
t
e
v
e
r
s
g
n
c
a
n
a
n
a
a
c
c
e
e
r
a
e
p
r
e
c
n
c
a
c
n
c
a
m
e
s
o
n
e
s
•
S
h
i
l
i
f
i
i
i
t
t
t
o
o
p
e
r
a
o
n
a
s
n
e
r
g
g
e
s
o
r
e
c
e
n
a
c
q
s
o
n
s
w
y
u
•
E
V
T
I
t
3
n
n
o
a
e
v		 f
A
l
1
i
d
l
l
t
t
t
t
t
e
a
s
s
r
a
e
g
c
e
a
o
r
e
a
r
y
a
s
s
e
s
•
(
(
C
)
E
i
i
i
d
X
t
v
v
e
e
n
n
m
o
r
e
n
n
o
v
a
o
u
n
p
s
e
g
s
e
e
g
u
r
e
•
,
…
P
h
I
I
I
d
i
D
i
P
d
P
h
I
I
b
i
h
i
d
2
7
7
t
t
t
t
t
a
s
e
a
a
n
a
e
p
p
a
n
a
s
e
s
a
r
n
p
r
o
c
w
u
•
d
l
h
i
t
t
e
e
o
p
m
e
n
p
a
r
n
e
r
s
p
p
s
v

Building innovative drug discovery alliances

Your contact:

Dr Werner LanthalerChief Executive Officer

+49.(0).40.560 81-242 +49.(0).40.560 81-333 Fax [email protected]

More from Evotec SE

Capital/Financing Update 2026
May 12
Regulatory Filings 2026
May 7
Regulatory Filings 2026
May 6
Interim / Quarterly Report 2026
May 6
Director's Dealing 2026
May 5
Regulatory Filings 2026
May 5
Regulatory Filings 2026
May 4
Regulatory Filings 2026
Apr 30
Report Publication Announcement 2026
Apr 29
Major Shareholding Notification 2026
Apr 28
View all filings →